ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Amoxapine. Amoxapine is rapidly and well absorbed following oral ingestion. Withdrawal emergent neurological signs have been associated with the discontinuation of amoxapine maintenance pharmacotherapy. Amoxapine is approximately 90% plasma protein bound. It has an apparent volume of distribution of 0.9 to 1.2 L/kg. The signs and symptoms of amoxapine overdosage include delirium, drowsiness, grand mal seizures, and lethargy with diminished deep tendon reflexes. Amoxapine overdosage requires emergency symptomatic medical support of body systems with attention to increasing amoxapine elimination and the prevention and control of seizures. Monitor patients, especially women, elderly patients, and patients who are receiving high-dosage amoxapine pharmacotherapy for EPRs, including tardive dyskinesia. Amoxapine overdosage has been associated with permanent neurological damage, cardiovascular and renal toxicity, and death.
